Lyra Therapeutics, Inc.

NasdaqGM:LYRA Rapporto sulle azioni

Cap. di mercato: US$17.0m

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Lyra Therapeutics Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Maria Palasis

Amministratore delegato

US$1.8m

Compenso totale

Percentuale dello stipendio del CEO32.7%
Mandato del CEO9.8yrs
Proprietà del CEOn/a
Durata media del management2.2yrs
Durata media del Consiglio di amministrazione4yrs

Aggiornamenti recenti sulla gestione

Recent updates

Will Lyra Therapeutics (NASDAQ:LYRA) Spend Its Cash Wisely?

Jan 25
Will Lyra Therapeutics (NASDAQ:LYRA) Spend Its Cash Wisely?

We Think Lyra Therapeutics (NASDAQ:LYRA) Needs To Drive Business Growth Carefully

Sep 10
We Think Lyra Therapeutics (NASDAQ:LYRA) Needs To Drive Business Growth Carefully

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Mar 12
Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Lyra Therapeutics appoints Nieman as Chief Medical Officer

Jul 05

Lyra Therapeutics: Progress In The Clinic

May 18

A First Look At Lyra Therapeutics

Apr 21

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Mar 30
Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Invest In Growth?

Dec 14
Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Invest In Growth?

We Think Lyra Therapeutics (NASDAQ:LYRA) Can Afford To Drive Business Growth

Aug 28
We Think Lyra Therapeutics (NASDAQ:LYRA) Can Afford To Drive Business Growth

We're Not Very Worried About Lyra Therapeutics' (NASDAQ:LYRA) Cash Burn Rate

May 04
We're Not Very Worried About Lyra Therapeutics' (NASDAQ:LYRA) Cash Burn Rate

How Many Lyra Therapeutics, Inc. (NASDAQ:LYRA) Shares Do Institutions Own?

Mar 05
How Many Lyra Therapeutics, Inc. (NASDAQ:LYRA) Shares Do Institutions Own?

Companies Like Lyra Therapeutics (NASDAQ:LYRA) Are In A Position To Invest In Growth

Jan 11
Companies Like Lyra Therapeutics (NASDAQ:LYRA) Are In A Position To Invest In Growth

Lyra Therapeutics down 19% underwhelming data from lead program

Dec 07

Lyra Therapeutics: An Intriguing Risk/Reward Proposition Tackling Chronic Rhinosinusitis

Nov 24

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Maria Palasis rispetto agli utili di Lyra Therapeutics?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024n/an/a

-US$101m

Mar 31 2024n/an/a

-US$69m

Dec 31 2023US$2mUS$583k

-US$63m

Sep 30 2023n/an/a

-US$62m

Jun 30 2023n/an/a

-US$61m

Mar 31 2023n/an/a

-US$60m

Dec 31 2022US$2mUS$583k

-US$55m

Sep 30 2022n/an/a

-US$55m

Jun 30 2022n/an/a

-US$51m

Mar 31 2022n/an/a

-US$48m

Dec 31 2021US$2mUS$552k

-US$44m

Sep 30 2021n/an/a

-US$37m

Jun 30 2021n/an/a

-US$32m

Mar 31 2021n/an/a

-US$26m

Dec 31 2020US$4mUS$471k

-US$22m

Sep 30 2020n/an/a

-US$20m

Jun 30 2020n/an/a

-US$18m

Mar 31 2020n/an/a

-US$17m

Dec 31 2019US$843kUS$388k

-US$17m

Compensazione vs Mercato: La retribuzione totale di Maria ($USD 1.79M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 679.79K ).

Compensazione vs guadagni: La retribuzione di Maria è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Maria Palasis (59 yo)

9.8yrs

Mandato

US$1,785,375

Compensazione

Dr. Maria Palasis, Ph D, serves as Director at PanTher Therapeutics, Inc. since June 2021. Dr. Palasis has been Chief Executive Officer, President and Director of Lyra Therapeutics, Inc. since January 2015...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Harlan Waksal
Executive Chairman2.7yrsUS$625.06k0.40%
$ 67.8k
Maria Palasis
CEO, President & Director9.8yrsUS$1.79mNessun dato
Carmichael Roberts
Co-Founderno dataNessun datoNessun dato
Jason Cavalier
CFO, Treasurer & Secretary3.1yrsUS$1.07mNessun dato
Ray Knox
Vice President of Operationsno dataNessun datoNessun dato
Ronan O'Brien
Chief Legal Officerless than a yearNessun datoNessun dato
Vineeta Belanger
Senior Vice President of Clinical Affairsno dataNessun datoNessun dato
Robert Richard
Senior Vice President of Technical Operations1.7yrsUS$666.79kNessun dato
Robert Kern
Chief Clinical Advisor3.7yrsNessun datoNessun dato
Gloria Cosgrove
Senior Vice President of Quality1.8yrsNessun datoNessun dato
Allison Nance
Senior Vice President of Regulatory Affairs1.8yrsNessun datoNessun dato
Elazer Edelman
VP of Finance & Riskno dataNessun datoNessun dato

2.2yrs

Durata media

59yo

Età media

Gestione esperta: Il team dirigenziale di LYRA è considerato esperto (durata media dell'incarico 2 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Harlan Waksal
Executive Chairman2.7yrsUS$625.06k0.40%
$ 67.8k
Maria Palasis
CEO, President & Director9.8yrsUS$1.79mNessun dato
James Tobin
Lead Independent Director2.6yrsUS$152.31k0%
$ 0
W. Smith
Independent Director4.9yrsUS$123.81k0%
$ 0
George Whitesides
Member of Scientific Advisory Board4yrsUS$333.93kNessun dato
C. Merrifield
Independent Director5.1yrsUS$113.06k0.017%
$ 2.9k
Robert Langer
Member of Scientific Advisory Board4yrsUS$19.36kNessun dato
Michael Dake
Member of Medical Advisory Boardno dataNessun datoNessun dato
William Gray
Member of Medical Advisory Boardno dataNessun datoNessun dato
Mahmood Razavi
Member of Medical Advisory Boardno dataNessun datoNessun dato
Gary Ansel
Member of Medical Advisory Boardno dataNessun datoNessun dato
I. Baumgartner
Member of Medical Advisory Boardno dataNessun datoNessun dato

4.0yrs

Durata media

73yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di LYRA sono considerati esperti (durata media dell'incarico 3.8 anni).